Trastuzumab-Related Cardiotoxicity and Cardiac Care In Patients with HER2 Positive Metastatic Breast Cancer

In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, HER2 targeted therapies have significantly improved survival.1,2 However, the cardiotoxicity associated with these therapies limits its use in some patients.3 In the metastatic setting HER2 targeted therapies are used until disease progression or toxicity.4,5 Although prolonged trastuzumab therapy may be associated with a higher risk of cardiotoxicity, this is felt to be counterbalanced by survival benefits of HER2 targeted therapy.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research